Aberdeen scientists to explore African seas for drug discoveries

Published: 9-Dec-2010
Research & Development

Research could lead to new treatments for cancer and MRSA

Scientists from Aberdeen’s Marine Biodiscovery Centre and the Division of Applied Medicine are to explore the seas off the coast of West Africa in research that could lead to the discovery of new treatments for diseases including cancer and MRSA.

A team will travel to Ghana next month to search the waters for unique marine organisms that could be used to develop new medicines.

The scientists hope to find previously undiscovered species of corals, sponges and sea squirts. They will examine these organisms for new molecules, bacteria and fungi, which could be used in the creation of new treatments for diseases prevalent in Africa – including tuberculosis and parasitic diseases such as malaria.

Professor Marcel Jaspars, director of the Marine Biodiscovery Centre, said: ‘Drug discovery work in West Africa has historically focused on land, investigating how molecules in plants can be used in the development of new medicines.

‘Our project marks the first time waters off the coast of West Africa have been explored to assess the diversity of marine organisms available in this area, and the potential they could harbour in the treatment of a number of diseases.’

Jaspars said the team would collect samples at low tide around the Gulf of Guinea and Guinea Basin, where they believe they will find new species.

The Aberdeen scientists will work with the University of Ghana during the trip, which marks the beginning of a three-year collaborative project between the two institutions.

The £1.6m Marine Biodiscovery Centre – which brings together chemists and biologists to work on the development of new pharmaceuticals from organisms from the depths of the world’s oceans – opened in June. It is one of only three in Europe dedicated to the exploration of the natural resources from our seas.

The project is funded by the Leverhulme Trust and co-ordinated by the Royal Society.

See more

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

Read more
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs

Trending Articles

  1. Echo MS+ integration enhances high-throughput mass spectrometry SCIEX expands compatibility with the ZenoTOF 8600 system to deliver greater sensitivity and automation capabilities
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy
  3. CARBOGEN AMCIS and Celonic unveil integrated ADC development platform at World ADC London 2026 The strategic alliance combines biologics and highly potent payload capabilities to streamline ADC development and manufacturing
  4. Promega unveils cellular target engagement technology TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery
  5. Sequential extraction kit enables multiomics analysis from a single sample Thermo Fisher Scientific launches a magnetic bead-based workflow to support genomic, transcriptomic and proteomic research

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now